Trastuzumab Deruxtecan in
            <i>HER2</i>
            -Mutant Non–Small-Cell Lung Cancer

Li, Bob T.; Smit, Egbert F.; Goto, Yasushi; Nakagawa, Kazuhiko; Udagawa, Hibiki; Mazières, Julien; Nagasaka, Misako; Bazhenova, Lyudmila; Saltos, Andreas; Felip, Enriqueta; Pacheco, Jose M.; Pérol, Maurice; Paz‐Ares, Luis; Saxena, Kapil; Shiga, Ryota; Cheng, Yun; Acharyya, Suddhasatta; Vitazka, Patrik; Shahidi, Javad; Planchard, David; Jänne, Pasi A.; Investigators, DESTINY-Lung Trial

doi:10.1056/nejmoa2112431

Cited by 584 publications

(499 citation statements)

References 42 publications

Supporting

Mentioning

485

Contrasting

Unclassified

Order By: Relevance

“…In addition, 80% of the patients experienced ILD presented with less than grade 2 ILD. 1,3 In our case, it was possible to get a durable response without the onset of ILD despite poor PS. With consideration of the high efficacy in the current case, T-DXd could be beneficial in patients with NSCLC harboring HER2 mutation with a poor PS.…”

Section: Discussionmentioning

confidence: 57%

“… 6 In the DISTNY-lung 01 trial, 26% of the participants experienced ILD. 1 On the contrary, the DESTINY-Breast01 trial showed that 13.6% of the participants. 3 These discrepancies between the two trials are associated with dose of T-DXd.…”

Section: Discussionmentioning

confidence: 98%

“…DESTINY-Lung01, a Phase II study, showed a promising clinical activity, with a high objective response (55%: 95% CI, 44 to 65) and durable responses as the median duration of response was 9.3 months (95% CI, 5.7 to 14.7), median progression-free survival was 8.2 months (95% CI, 6.0 to 11.9) and median overall survival was 17.8 months (95% CI, 13.8 to 22.1). 1 On the contrary, this clinical trial only included patients with PS score of 0 or 1. Our case suggested the efficacy and safety of T-DXd was maintained in patients with advanced-stage NSCLC who have PS score of 2 or higher.…”

Section: Discussionmentioning

confidence: 99%

“…Human epidermal growth factor receptor 2 ( HER2 ) gene mutation is an oncogenic driver mutation that can be a treatment target. 1 The recently developed anti- HER2 antibody–drug conjugate (ADC) was effective for the treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring HER2 mutation. 1 , 2 However, to the best of our knowledge, no previous study has shown that ADCs including trastuzumab deruxtecan (T-DXd), which are used against advanced-stage NSCLC harboring HER2 mutation, are effective and safe in patients with a poor performance status (PS).…”

Section: Introductionmentioning

confidence: 99%

“… 1 The recently developed anti- HER2 antibody–drug conjugate (ADC) was effective for the treatment of advanced-stage non-small-cell lung cancer (NSCLC) harboring HER2 mutation. 1 , 2 However, to the best of our knowledge, no previous study has shown that ADCs including trastuzumab deruxtecan (T-DXd), which are used against advanced-stage NSCLC harboring HER2 mutation, are effective and safe in patients with a poor performance status (PS). Herein, we report a case of NSCLC harboring HER2 exon 20 insertion mutation in a patient who had significantly good tumor response and who experienced improvement in systemic conditions after treatment with T-DXd despite a poor PS.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

Kato¹,

Kato²,

Minegishi³

et al. 2021

OTT

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

Kato¹,

Kato²,

Minegishi³

et al. 2021

OTT

View full text Add to dashboard Cite

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

Choi

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceOver the past 10 years, treatment of non–small cell lung cancer (NSCLC) has been continually revolutionized. However, standard clinical trials may not reflect current multiple lines of treatment and corresponding outcomes in a timely manner.ObjectiveTo investigate outcomes associated with new treatment of NSCLC in a clinical setting.Design, Setting, and ParticipantsThis cohort study included patients with NSCLC between January 1, 2010, and November 30, 2020, who received any anticancer treatment at Samsung Medical Center in Korea. Data were analyzed from November 2021 through February 2022.ExposuresClinical and pathological stage, histology, and major druggable sequence variation, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, RET, MET exon 14 skipping, BRAF V600E, KRAS G12C, and NTRK between 2 periods (period I: 2010-2015 vs period II: 2016–2020).Main Outcomes and MeasuresThe primary outcome was the 3-year survival rate of NSCLC. Secondary outcomes included median overall survival, progression-free survival, and recurrence-free survival.ResultsAmong 21 978 patients with NSCLC (median [range] age at diagnosis, 64.1 [57.0-71.0] years; 13 624 males [62.0%]), there were 10 110 patients in period I and 11 868 patients in period II; adenocarcinoma (AD) was the predominant histology (7112 patients [70.3%] in period I and 8813 patients [74.3%] in period II). There were 4224 never smokers [41.8%] in period I and 5292 never smokers [44.6%] in period II. Compared with patients in period I, patients during period II were more likely to undergo molecular tests in the AD (5678 patients [79.8%] vs 8631 patients [97.9%]) and non-AD (1612 of 2998 patients [53.8%] and 2719 of 3055 patients [89.0%]) groups. In patients with AD in period I, 3-year survival rates were 92.8% (95% CI, 91.8%-93.7%), 72.4% (95% CI, 68.3%-76.8%), 56.7% (95% CI, 53.4%-60.2%), and 28.7% (95% CI, 27.0%-30.4%) for stage I, II, III, and IV, respectively. In period II, 3-year survival rates of patients with AD were 95.1% (95% CI, 94.4%-95.9%), 82.5% (95% CI, 79.1%-86.1%), 65.1% (95% CI, 61.8%-68.6%), and 42.4% (95% CI, 40.3%-44.7%) for each stage, respectively. In patients without AD, 3-year survival rates were 72.0% (95% CI, 68.8%-75.3%), 60.0% (95% CI, 56.2%-64.1%), 38.9% (95% CI, 35.6%-42.5%), and 9.7% (95% CI, 7.9%-12.1%) for each stage in period I. In period II, the 3-year survival rates of patients without AD were 79.3% (95% CI, 76.3%-82.4%), 67.3% (95% CI, 62.8%-72.1%), 48.2% (95% CI, 44.5%-52.3%), and 18.1% (95% CI, 15.1%-21.6%) for each stage.Conclusions and RelevanceIn this cohort study of 10 years of clinical data, survival outcomes were improved across all stages, with larger increases in patients with stage III to IV disease. The incidence of never-smokers and the use of molecular testing increased.

show abstract